Table 4.
Frequency and type of new or worsening neurological symptoms.
| Muscle weakness | Visual symptoms | Gait instability | Increased pain | Sensory disturbances | Sphincteric problems | |
|---|---|---|---|---|---|---|
| Number of responders (%) * | 30 (6.8%) | 13 (3%) | 17 (3.9%) | 31 (7.1%) | 48 (11%) | 13 (3%) |
| Number of responders <55 years old (%) ⁎⁎ | 19 (63.3%) |
11 (85%) |
10 (58.8%) | 19 (61.3%) | 29 (60.4%) |
7 (53.9%) |
| One dose | 8 (26.7%) | 2 (15.4%) | 6 (35.3%) | 7 (22.6%) | 9 (18.8%) | 5 (38.5%) |
| Two doses | 11 (36.7%) |
9 (69.2%) |
4 (23.6%) |
12 (38.8%) | 20 (41.7%) |
2 (15.4%) |
| Number of responders >55 years** old (%) | 11 (36.7%) |
2 (15.4%) |
7 (41.2%) |
12 (38.8%) | 19 (39.6% |
6 (46.1%) |
| One dose | 3 (10%) | 0 | 3 (17.7%) | 3 (9.7%) | 7 (14.6%) | 0 |
| Two doses | 8 (26.7%) | 2 (15.4%) | 4 (23.6%) | 9 (29.1%) | 12 (25%) | 6 (46.1%) |
| Number of responders treated with immunotherapies (%) ⁎⁎ | 22 (73.3%) |
9 (69.2%) |
13 (76.5%) | 24 (77.4%) | 32 (66.7%) |
9 (69.3%) |
| One dose | 9 (30%) |
2 (15.4%) |
7 (41.2%) |
10 (32.3%) | 10 (20.9%) |
4 (30.8%) |
| Two doses | 13 (43.3%) |
7 (53.9%) |
6 (35.3%) |
14 (45.2%) | 22 (45.9%) |
5 (38.5%) |
| Number of responders not treated** with immunotherapies (%) | 8 (26.7%) | 6 (46.2%) | 4 (23.6%) | 7 (22.6%) | 16 (33.3%) | 4 (30.8%) |
| One dose | 5 (16.7%) | 3 (23.1%) | 3 (17.7%) | 2 (6.5%) | 7 (14.6%) | 2 (15.4%) |
| Two doses | 3 (10%) | 3 (23.1%) | 1 (5.9%) | 5 (16.2%) | 9 (18.8%) | 2 (15.4%) |
⁎
Out of the total number of responders; some participants reported more than one event
⁎⁎
Out of the responders who reported the specific event